{"id":40031,"date":"2023-03-13T17:35:34","date_gmt":"2023-03-13T09:35:34","guid":{"rendered":"http:\/\/biopioneer.com.tw\/?p=40031"},"modified":"2023-03-28T11:44:54","modified_gmt":"2023-03-28T03:44:54","slug":"vegf%e6%8a%97%e9%ab%94-vegf-antibody%e8%b2%a8%e8%99%9fir108-442-ireal-biotechnology-%e8%89%be%e9%8b%ad%e7%94%9f%e6%8a%80","status":"publish","type":"post","link":"http:\/\/biopioneer.com.tw\/?p=40031","title":{"rendered":"VEGF\u6297\u9ad4 | VEGF antibody\u8ca8\u865fIR108-442 (IReal Biotechnology \u827e\u92ed\u751f\u6280)"},"content":{"rendered":"

IHC\/WB\/IF\/IP\u7814\u7a76\u5de5\u5177-Angiogenesis \/ Endothelial Antibodies<\/strong><\/span>–IReal Biotechnology<\/span><\/span><\/p>\n

\u8840\u7ba1\u5167\u76ae\u751f\u9577\u56e0\u5b50 (Vascular endothelial growth factor, VEGF) \u662f\u4e00\u7a2e\u5728\u8840\u7ba1\u65b0\u751f(angiogenesis)\u3001\u8840\u7ba1\u751f\u6210(vasculogenesis )\u548c\u5167\u76ae\u7d30\u80de\u751f\u9577(endothelial cell growth)\u4e2d\u5177\u6709\u6d3b\u6027\u7684\u751f\u9577\u56e0\u5b50\u3002\u8a98\u5c0e\u5167\u76ae\u7d30\u80de(endothelial cell )\u589e\u6b96(cell proliferation)\uff0c\u4fc3\u9032\u7d30\u80de\u9077\u79fb(cell migration)\uff0c\u6291\u5236\u7d30\u80de\u51cb\u4ea1(\u00a0apoptosis )\uff0c\u8a98\u5c0e\u8840\u7ba1\u900f\u5316(permeabilization)\u3002\u7d50\u5408 FLT1\/VEGFR1 \u548c KDR\/VEGFR2 \u53d7\u9ad4\u3001\u786b\u9178\u4e59\u9170\u809d\u7d20\u548c\u809d\u7d20\u3002 NRP1\/Neuropilin-1 \u7d50\u5408\u540c\u7a2e\u578b VEGF-165 \u548c VEGF-145\u3002\u7570\u69cb\u9ad4 VEGF165B \u8207 KDR \u7d50\u5408\u4f46\u4e0d\u6fc0\u6d3b\u4e0b\u6e38\u4fe1\u865f\u901a\u8def\uff0c\u4e0d\u6fc0\u6d3b\u8840\u7ba1\u751f\u6210(\u00a0angiogenesis )\u4e26\u6291\u5236\u816b\u7624\u751f\u9577(tumor growth)\u3002<\/p>\n

\"\"<\/p>\n

\"HOT\"<\/a>VEGF\u6297\u9ad4 | VEGF antibody\u8ca8\u865fIR108-442\u00a0 (IReal Biotechnology \u827e\u92ed\u751f\u6280)<\/a><\/span><\/span><\/strong><\/span><\/p>\n

VEGF antibody (IReal Biotechnology \u827e\u92ed\u751f\u6280,IR108-442)<\/p>\n

iReal \u827e\u92b3\u751f\u6280\u7368\u5bb6\u6253\u9020\u51faMonoclonal-like Polyclonal Antibody\uff0c\u514d\u75ab\u539f(Immunogen)\u70ba\u61c9\u7528\u77ed\u93c8\u80dc\u80bd(peptide)\u70ba\u6297\u539f\u8a2d\u8a08\u51fa\u767c\u9ede\uff0c\u6311\u9078\u5404\u86cb\u767d\u6700\u4f73\u7684\u4f4d\u9ede(epitope) \u8fa8\u8b58\u4f4d\u4f86\u8fa8\u8a8d\u76ee\u6a19\u86cb\u767d\uff0ciReal\u00a0\u514d\u75ab\u8840\u6e05\u7d93\u904e\u4e00\u9023\u591a\u6b65\u9a5f\u7684\u7d14\u5316\u904e\u7a0b(Affinity column purified )\uff0c\u53bb\u9664\u6389\u5404\u7a2e\u975e\u5c08\u4e00\u6027\u7684\u86cb\u767d\uff0c\u4ee5\u964d\u4f4e\u6297\u9ad4\u7684\u80cc\u666f\u503c\uff1b\u540c\u6642\u85c9\u7531\u5154\u5b50\u7368\u7279\u7684\u514d\u75ab\u7cfb\u7d71\u6240\u7522\u751f\u7684\u6297\u9ad4\uff0c\u80fd\u5920\u7522\u2f63\u8a31\u591a\u2f7c\u2fcf\u514d\u75ab\u7cfb\u7d71\u4e0d\u80fd\u8b58\u5225\u7684\u6297\u539f\u7684\u6297\u9ad4\u3002\u64c1\u6709\u5404\u5b78\u8853\u55ae\u4f4d\u771f\u5be6\u6578\u64da\u7684\u9a57\u8b49\uff0c\u4e26\u5177\u5099\u81e8\u5e8a\u9a57\u8b49\u898f\u683c\u7684\u6297\u9ad4\u54c1\u8cea\uff0c\u5927\u91cf\u4e14\u73fe\u8ca8\u4f9b\u61c9\u3002<\/p>\n

VEGF antibody\u00a0<\/span>(Endogenous)\uff0c\u91dd\u5c0dVEGF\u5177\u6709\u5c08\u4e00\u8868\u73fe\uff0c\u53ef\u61c9\u7528\u65bcWestern Blot\u3001IF\u3001IHC(Paraffin)\u3001IP\u5be6\u9a57\uff0c\u7269\u7a2e\u4f86\u6e90\u70baRabbit-IgG\uff0c\u53cd\u61c9\u7269\u7a2e: Human\u3001Mouse\u3001Rat\u3002<\/p>\n

Weatern Blot\u64cd\u4f5c\u624b\u518a<\/a><\/span><\/p>\n

Western Blot 1:500\u20131:1000
\nImmunofluorescence 1:200\u20131:500
\nImmunohistochemistry (Paraffin) 1:100\u20131:300
\nImmunoprecipitation : Reported in the literature, not verified in house.<\/p>\n

VEGF \u6297\u9ad4Vimentin antibody\u7522\u54c1\u4ecb\u7d39:<\/span><\/strong><\/span><\/p>\n

This gene is a member of the PDGF\/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]<\/p>\n

\u8a72\u57fa\u56e0\u662f PDGF\/VEGF \u751f\u9577\u56e0\u5b50\u5bb6\u65cf\u7684\u6210\u54e1\u3002\u5b83\u7de8\u78bc\u809d\u7d20\u7d50\u5408\u86cb\u767d\uff0c\u4ee5\u4e8c\u786b\u9375\u9023\u63a5\u7684\u540c\u578b\u4e8c\u805a\u9ad4\u5f62\u5f0f\u5b58\u5728\u3002\u9019\u7a2e\u751f\u9577\u56e0\u5b50\u8a98\u5c0e\u8840\u7ba1\u5167\u76ae\u7d30\u80de\u7684\u589e\u6b96\u548c\u9077\u79fb\uff0c\u5c0d\u751f\u7406\u6027\u548c\u75c5\u7406\u6027\u8840\u7ba1\u751f\u6210\u90fd\u662f\u5fc5\u4e0d\u53ef\u5c11\u7684\u3002\u5728\u5c0f\u9f20\u4e2d\u7834\u58de\u8a72\u57fa\u56e0\u6703\u5c0e\u81f4\u7570\u5e38\u7684\u80da\u80ce\u8840\u7ba1\u5f62\u6210\u3002\u8a72\u57fa\u56e0\u5728\u8a31\u591a\u5df2\u77e5\u816b\u7624\u4e2d\u88ab\u4e0a\u8abf\uff0c\u5176\u8868\u9054\u8207\u816b\u7624\u5206\u671f\u548c\u9032\u5c55\u76f8\u95dc\u3002\u5728\u60a3\u6709 POEMS \u7d9c\u5408\u5fb5\uff08\u4e5f\u7a31\u70ba Crow-Fukase \u7d9c\u5408\u5fb5\uff09\u7684\u60a3\u8005\u4e2d\u767c\u73fe\u9019\u7a2e\u86cb\u767d\u8cea\u6c34\u5e73\u5347\u9ad8\u3002\u8a72\u57fa\u56e0\u7684\u7b49\u4f4d\u57fa\u56e0\u8b8a\u7570\u8207\u7cd6\u5c3f\u75c5 1 (MVCD1) \u548c\u52d5\u8108\u7ca5\u6a23\u786c\u5316\u7684\u5fae\u8840\u7ba1\u4e26\u767c\u75c7\u6709\u95dc\u3002\u5df2\u7d93\u63cf\u8ff0\u4e86\u7de8\u78bc\u4e0d\u540c\u4e9e\u578b\u7684\u9078\u64c7\u6027\u526a\u63a5\u8f49\u9304\u7269\u8b8a\u9ad4\u3002\u9084\u6709\u8b49\u64da\u8868\u660e\uff0c\u5f9e\u4e0a\u6e38\u975e AUG (CUG) \u5bc6\u78bc\u5b50\u958b\u59cb\u7684\u66ff\u4ee3\u7ffb\u8b6f\u6703\u7522\u751f\u984d\u5916\u7684\u4e9e\u578b\u3002\u6700\u8fd1\u7684\u4e00\u9805\u7814\u7a76\u8868\u660e\uff0c\u901a\u904e\u7d42\u6b62\u5bc6\u78bc\u5b50\u901a\u8b80\u6a5f\u5236\u4f7f\u7528\u66ff\u4ee3\u7684\u6846\u5167\u7ffb\u8b6f\u7d42\u6b62\u5bc6\u78bc\u5b50\u53ef\u7522\u751f C \u672b\u7aef\u64f4\u5c55\u7684\u540c\u7a2e\u578b\uff0c\u4e26\u4e14\u9019\u7a2e\u540c\u7a2e\u578b\u5177\u6709\u6297\u8840\u7ba1\u751f\u6210\u4f5c\u7528\u3002\u4f86\u81ea AUG \u8d77\u59cb\u5bc6\u78bc\u5b50\u7684\u4e00\u4e9b\u540c\u7a2e\u578b\u7684\u8868\u9054\u53d7\u4e00\u500b\u5c0f\u7684\u4e0a\u6e38\u958b\u653e\u95b1\u8b80\u6846\u7684\u8abf\u7bc0\uff0c\u8a72\u95b1\u8b80\u6846\u4f4d\u65bc\u5167\u90e8\u6838\u91a3\u9ad4\u9032\u5165\u4f4d\u9ede\u5167\u3002\u5728\u611f\u67d3\u56b4\u91cd\u6025\u6027\u547c\u5438\u7cfb\u7d71\u7d9c\u5408\u75c7\u51a0\u72c0\u75c5\u6bd2 2 (SARS-CoV-2) \u671f\u9593\uff0cVEGF \u7684\u6c34\u5e73\u6703\u589e\u52a0\uff0c\u5f9e\u800c\u901a\u904e\u4fc3\u9032\u708e\u75c7\u7d30\u80de\u7684\u52df\u96c6\u548c\u589e\u52a0\u8840\u7ba1\u751f\u6210\u7d20 II (Ang II) \u7684\u6c34\u5e73\u4f86\u4fc3\u9032\u708e\u75c7\uff0c\u8840\u7ba1\u751f\u6210\u7d20 II (Ang II) \u662f\u5169\u7a2e\u7522\u7269\u4e4b\u4e00SARS-CoV-2 \u7d50\u5408\u9776\u9ede\uff0c\u8840\u7ba1\u7dca\u5f35\u7d20\u8f49\u63db\u9176 2 (ACE2)\u3002\u53cd\u904e\u4f86\uff0cAng II \u4fc3\u9032 VEGF \u5347\u9ad8\uff0c\u5f9e\u800c\u5f62\u6210\u708e\u75c7\u7d30\u80de\u56e0\u5b50\u91cb\u653e\u7684\u60e1\u6027\u5faa\u74b0\u3002[\u7531 RefSeq \u63d0\u4f9b\uff0c2020 \u5e74 6 \u6708]<\/p>\n

\"\u7db2\u7ad9\u898f\u683c\u5c0f\u5716_\u5de5\u4f5c\u5340\u57df<\/a><\/p>\n

 <\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4WB\u5716\u50cf\"<\/p>\n

\u6297VEGF\u6297\u9ad4WB\u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n1\/1000 \u7a00\u91cb\u7684 VEGF \u6297\u9ad4
\n\u88c2\u89e3\u7269\/\u86cb\u767d\u8cea\uff0c\u6bcf\u6cf3\u9053 35 \u03bcg\u3002
\n\u8a72\u5370\u8de1\u662f\u4f7f\u7528 15% SDS-PAGE \u751f\u6210\u7684\u3002<\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4IHC\u5716\u50cfVEGF\u6297\u9ad4\"<\/p>\n

\u6297VEGF\u6297\u9ad4IHC\u5716\u50cfVEGF\u6297\u9ad4(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u7528 IR108-442 \u5728 1\/200 RT 1 \u5c0f\u6642\u5c0d\u77f3\u881f\u5305\u57cb\u5c0f\u9f20\u80ba\u6a19\u8a18 VEGF \u9032\u884c\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u5206\u6790\u3002\u8868\u4f4d\u6aa2\u7d22\u65b9\u6cd5\uff1a\u6ab8\u6aac\u9178\u9e7d\u7de9\u885d\u6db2\uff0cpH 6.0<\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4IHC\u5716\u50cfVEGF\u6297\u9ad4\"<\/p>\n

\u6297VEGF\u6297\u9ad4IHC\u5716\u50cfVEGF\u6297\u9ad4(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u7528 IR108-442 \u5728 1\/200 RT 1 \u5c0f\u6642\u5c0d\u77f3\u881f\u5305\u57cb\u7684\u5c0f\u9f20\u7d50\u8178\u6a19\u8a18 VEGF \u9032\u884c\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u5206\u6790\u3002\u8868\u4f4d\u6aa2\u7d22\u65b9\u6cd5\uff1a\u6ab8\u6aac\u9178\u9e7d\u7de9\u885d\u6db2\uff0cpH 6.0<\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4_\u4e73\u817a\u764cIHC\u5716\u50cf\"<\/p>\n

\u6297VEGF\u6297\u9ad4_\u4e73\u817a\u764cIHC\u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u77f3\u881f\u5305\u57cb\u7684\u4eba\u4e73\u817a\u764c\u7d44\u7e54\u7528 1\/100 \u7684 IR108-442 \u6a19\u8a18 VEGF \u7684\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u5206\u6790\u3002<\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4_\u7d50\u76f4\u8178\u764cIHC\u5716\u50cf\"<\/p>\n

\u6297VEGF\u6297\u9ad4_\u7d50\u76f4\u8178\u764cIHC\u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u77f3\u881f\u5305\u57cb\u7684\u4eba\u7d50\u76f4\u8178\u764c\u7d44\u7e54\u7528 1\/100 \u7684 IR108-442 \u6a19\u8a18 VEGF \u7684\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u5206\u6790\u3002<\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4_\u5c0f\u9f20\u7d44\u7e54IHC\u5716\u50cf\"<\/p>\n

\u6297VEGF\u6297\u9ad4_\u5c0f\u9f20\u7d44\u7e54IHC\u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u7528 IR108-442 \u5728 1\/100 RT 1 \u5c0f\u6642\u5c0d\u77f3\u881f\u5305\u57cb\u7684\u5c0f\u9f20\u7d44\u7e54\u6a19\u8a18 VEGF \u9032\u884c\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u5206\u6790\u3002
\n\u8868\u4f4d\u4fee\u5fa9\u65b9\u6cd5\uff1a\u6ab8\u6aac\u9178\u9e7d\u7de9\u885d\u6db2\uff0cpH 6.0<\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4_\u5c0f\u9f20\u7d44\u7e54IHC\u5716\u50cf\"<\/p>\n

\u6297VEGF\u6297\u9ad4_\u5c0f\u9f20\u7d44\u7e54IHC\u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u7528 IR108-442 \u5728 1\/100 RT 1 \u5c0f\u6642\u5c0d\u77f3\u881f\u5305\u57cb\u7684\u5c0f\u9f20\u7d44\u7e54\u6a19\u8a18 VEGF \u9032\u884c\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u5206\u6790\u3002
\n\u8868\u4f4d\u4fee\u5fa9\u65b9\u6cd5\uff1a\u6ab8\u6aac\u9178\u9e7d\u7de9\u885d\u6db2\uff0cpH 6.0<\/p>\n

\"IR108-442<\/p>\n

\u6297 VEGF \u6297\u9ad4 ICC\/IF \u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u514d\u75ab\u7192\u5149\uff1a\u7d30\u80de\u5728\u5ba4\u6eab\u4e0b\u7528 4% \u591a\u805a\u7532\u919b\u56fa\u5b9a 10 \u5206\u9418\uff0c\u5728\u5ba4\u6eab\u4e0b\u7528 0.1% NP-40 \u900f\u5316 10 \u5206\u9418\uff0c\u7136\u5f8c\u5728\u5ba4\u6eab\u4e0b\u7528 5% BSA \u5c01\u9589 30 \u5206\u9418\u3002\u7d30\u80de\u5728 1:200 \u548c 4\u00b0C \u4e0b\u7528 IR108-442 \u6297 VEGF \u6297\u9ad4\uff08\u7d05\u8272\uff09\u67d3\u8272\u3002DAPI\uff08\u85cd\u8272\uff09\u7528\u4f5c\u6838\u8907\u67d3\u5291\u3002<\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4WB\u5716\u50cf\"<\/p>\n

\u6297VEGF\u6297\u9ad4WB\u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n1\/1000 \u7a00\u91cb\u7684 VEGF \u6297\u9ad4
\n\u88c2\u89e3\u7269\/\u86cb\u767d\u8cea\uff0c\u6bcf\u6cf3\u9053 35 \u03bcg\u3002
\n\u8a72\u5370\u8de1\u662f\u4f7f\u7528 15% SDS-PAGE \u751f\u6210\u7684\u3002<\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4_\u814e\u764cIHC\u5716\u50cf\"<\/p>\n

\u6297VEGF\u6297\u9ad4_\u814e\u764cIHC\u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u77f3\u881f\u5305\u57cb\u7684\u4eba\u814e\u764c\u7d44\u7e54\u7528 1\/100 \u7684 IR108-442 \u6a19\u8a18 VEGF \u7684\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u5206\u6790\u3002<\/p>\n

\"IR108-442<\/p>\n

\u6297 VEGF \u6297\u9ad4 IHC \u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u77f3\u881f\u5305\u57cb\u7684\u4eba\u809d\u764c\u548c\u777e\u4e38\u764c\u7d44\u7e54\u7528 1\/100 \u7684 IR108-442 \u6a19\u8a18 VEGF \u7684\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u5206\u6790\u3002<\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4_\u5c0f\u9f20\u7d44\u7e54IHC\u5716\u50cf\"<\/p>\n

\u6297VEGF\u6297\u9ad4_\u5c0f\u9f20\u7d44\u7e54IHC\u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u7528 IR108-442 \u5728 1\/100 RT 1 \u5c0f\u6642\u5c0d\u77f3\u881f\u5305\u57cb\u7684\u5c0f\u9f20\u7d44\u7e54\u6a19\u8a18 VEGF \u9032\u884c\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u5206\u6790\u3002
\n\u8868\u4f4d\u4fee\u5fa9\u65b9\u6cd5\uff1a\u6ab8\u6aac\u9178\u9e7d\u7de9\u885d\u6db2\uff0cpH 6.0<\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4_\u5c0f\u9f20\u7d44\u7e54IHC\u5716\u50cf\"<\/p>\n

\u6297VEGF\u6297\u9ad4_\u5c0f\u9f20\u7d44\u7e54IHC\u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u7528 IR108-442 \u5728 1\/100 RT 1 \u5c0f\u6642\u5c0d\u77f3\u881f\u5305\u57cb\u7684\u5c0f\u9f20\u7d44\u7e54\u6a19\u8a18 VEGF \u9032\u884c\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u5206\u6790\u3002
\n\u8868\u4f4d\u4fee\u5fa9\u65b9\u6cd5\uff1a\u6ab8\u6aac\u9178\u9e7d\u7de9\u885d\u6db2\uff0cpH 6.0<\/p>\n

\"IR108-442\u6297VEGF\u6297\u9ad4_\u5c0f\u9f20\u7d44\u7e54IHC\u5716\u50cf\"<\/p>\n

\u6297VEGF\u6297\u9ad4_\u5c0f\u9f20\u7d44\u7e54IHC\u5716\u50cf(IREAL, #IR108-442)<\/span><\/strong><\/span>
\n\u7528 IR108-442 \u5728 1\/100 RT 1 \u5c0f\u6642\u5c0d\u77f3\u881f\u5305\u57cb\u7684\u5c0f\u9f20\u7d44\u7e54\u6a19\u8a18 VEGF \u9032\u884c\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u5206\u6790\u3002
\n\u8868\u4f4d\u4fee\u5fa9\u65b9\u6cd5\uff1a\u6ab8\u6aac\u9178\u9e7d\u7de9\u885d\u6db2\uff0cpH 6.0<\/p>\n\n\n\n\n\n\n\n
IR300-981<\/td>\nCD9<\/a><\/span><\/td>\nExosome Biomarker<\/td>\nRabbit<\/td>\nH,M,R<\/td>\nWB, IF, IHC<\/td>\n<\/tr>\n
IR301-983<\/td>\nCD63<\/a><\/span><\/td>\nExosome Biomarker<\/td>\nRabbit<\/td>\nH,M,R<\/td>\nWB, IHC, FC<\/td>\n<\/tr>\n
IR302-986<\/td>\nCD81<\/a><\/span><\/td>\nExosome Biomarker<\/td>\nRabbit<\/td>\nH,M,R<\/td>\nWB, IF, IHC<\/td>\n<\/tr>\n
IR304-990<\/td>\nFlotillin-1<\/td>\nExosome Biomarker<\/td>\nRabbit<\/td>\nH,M,R<\/td>\nWB, IF, IHC<\/td>\n<\/tr>\n
IR303-988<\/td>\nALIX\u6297\u9ad4<\/a><\/span><\/td>\nExosome Biomarker<\/td>\nRabbit<\/td>\nH,M,R<\/td>\nWB, IF, IHC<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"\"<\/p>\n

IHC\/\u75c5\u7406\u5b78\u6297\u9ad4(IHC\/Pathology antibodies)<\/span><\/strong><\/span><\/p>\n

Please note that related Positive Control Slides are also available. \u5206\u5b50\u75c5\u7406\u5b78(molecular pathology)\u4e2d\u7684\u514d\u75ab\u7d44\u7e54\u5316\u5b78(Immunohistochemistry)\u626e\u6f14\u91cd\u8981\u4f5c\u7528\uff1a\u8a3a\u65b7(Diagnosis)\u3001\u9810\u5f8c(Prognosis)\u548c\u9810\u6e2c(Predictive)\u3002 IHC \u6297\u9ad4(IHC antibodies)\u5df2\u88ab\u78ba\u5b9a\u70ba\u7528\u65bc\u798f\u723e\u99ac\u6797\u56fa\u5b9a\u77f3\u881f\u5207\u7247(formalin-fixed paraffin sections)\u514d\u75ab\u7d44\u7e54\u5316\u5b78(immunohistochemistry)\u7684\u6700\u4f73\u8a66\u5291\u3002\u6240\u6709 IHC\/\u75c5\u7406\u5b78\u6297\u9ad4(IHC\/Pathology antibodies)\u50c5\u4f9b\u7814\u7a76\u4f7f\u7528\u3002IHC\/\u75c5\u7406\u5b78\u6297\u9ad4\u5df2\u7d93\u91dd\u5c0d\u4eba\u9ad4\/\u8001\u9f20\/\u5927\u9f20\u7d44\u7e54\u7684\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u9032\u884c\u4e86\u5ee3\u6cdb\u7684\u6e2c\u8a66\u548c\u9a57\u8b49(Pathology validated)\uff0c\u4e26\u7d93\u904e\u7cbe\u5fc3\u8a2d\u8a08\uff0c\u53ef\u63d0\u4f9b\u4e00\u81f4\u3001\u7279\u7570\u6027\u548c\u654f\u611f\u7684\u67d3\u8272\u3002<\/p>\n

PD-1\u75c5\u7406\u5b78\u6297\u9ad4\uff1a<\/span>\u7a0b\u5e8f\u6027\u6b7b\u4ea1 1 (Programmed Death 1, PD-1) \u662f T \u7d30\u80de\u8abf\u7bc0\u5291(T-cell regulators) CD28\/CTLA-4 \u5bb6\u65cf\u7684\u6210\u54e1\uff0c\u5728\u6d3b\u5316\u7684 T \u7d30\u80de\u3001B \u7d30\u80de\u548c\u5de8\u566c\u7d30\u80de\u8868\u9762\u8868\u9054\u70ba\u5171\u53d7\u9ad4(co-receptor)\u3002\u65b0\u7684\u7814\u7a76\u8868\u660e\uff0cPD-1\/PD-L1 \u4fe1\u865f\u901a\u8def\u53ef\u80fd\u8207\u6297\u816b\u7624\u514d\u75ab\u6709\u95dc\uff0c\u56e0\u70ba PD-L1 \u5df2\u88ab\u8b49\u660e\u53ef\u8a98\u5c0e\u6d3b\u5316 T \u7d30\u80de\u51cb\u4ea1(apoptosis)\u6216\u6291\u5236\u7d30\u80de\u6bd2\u6027 T \u7d30\u80de(cytotoxic T cells)\u7684\u6d3b\u6027\u3002\u8207 CD10 \u548c BCL6 \u4e0d\u540c\uff0cPD-1 \u50c5\u7531\u5c11\u6578 B \u7d30\u80de\u8868\u9054\uff0c\u56e0\u6b64\u6297 PD-1 \u53ef\u80fd\u662f\u8840\u7ba1\u514d\u75ab\u6bcd\u7d30\u80de\u6027\u6dcb\u5df4\u7624(angioimmunoblastic lymphoma)\u4e2d\u66f4\u7279\u7570\u548c\u6709\u7528\u7684\u8a3a\u65b7\u6a19\u8a8c\u7269\u3002>>\u00a0PD-L1\/CD274 C\u672b\u7aef\u6297\u9ad4<\/a><\/span><\/p>\n

CTLA4\u75c5\u7406\u5b78\u6297\u9ad4\uff1a<\/span>CD152 \u6297\u539f\uff0c\u4e5f\u7a31\u70ba CTLA4\uff0c\u662f\u4e00\u7a2e\u5c6c\u65bc\u514d\u75ab\u7403\u86cb\u767d\u8d85\u5bb6\u65cf(immunoglobulin superfamily)\u7684\u5b8c\u6574\u819c\u86cb\u767d\uff0c\u5176\u8868\u9054\u70ba 30 kDa \u55ae\u9ad4(30 kDa monomer)\u6216\u4e8c\u786b\u9375\u9023\u63a5\u7684\u540c\u578b\u4e8c\u805a\u9ad4(disulfide-linked homodimer)\u3002\u5b83\u8207T\u7d30\u80de\u6297\u539fCD28(T cell antigen CD28)\u5177\u6709\u540c\u6e90\u6027\uff0c\u8207CD28\u4e00\u6a23\uff0c\u662fCD80\u548cCD86\u7684\u914d\u9ad4(ligand)\u3002 CTLA-4 \u662f T \u8f14\u52a9\u7d30\u80de\u4e0a\u7684\u4e00\u7a2e\u53d7\u9ad4\uff0c\u53ef\u4f5c\u70ba\u514d\u75ab\u6aa2\u67e5\u9ede(immune checkpoint)\u548c\u514d\u75ab\u53cd\u61c9\u7684\u4e0b\u8abf\u56e0\u5b50\u3002 CTLA-4 \u7684\u7a81\u8b8a\u8207\u8a31\u591a\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5(autoimmune diseases)\u6709\u95dc\u3002<\/p>\n

Lp-PLA2\u75c5\u7406\u5b78\u6297\u9ad4\uff1a<\/span>Lp-PLA2\uff0c\u4e5f\u7a31\u70ba\u8102\u86cb\u767d\u76f8\u95dc\u78f7\u8102\u9176 A2 (Lipoprotein-associated Phospholipase A2)\u6216\u8840\u5c0f\u677f\u6d3b\u5316\u56e0\u5b50\u4e59\u9170\u6c34\u89e3\u9176 (platelet-activating factor acetylhydrolase , PAF-AH)\uff0c\u662f\u4e00\u7a2e\u7531\u708e\u75c7\u7d30\u80de(inflammatory cells )\u7522\u751f\u7684\u9176\uff0c\u5176\u529f\u80fd\u662f\u4f7f\u8840\u5c0f\u677f\u6d3b\u5316\u56e0\u5b50(platelet-activating factor)\u5931\u6d3b\u548c\u964d\u89e3(degrade)\uff0c\u8840\u5c0f\u677f\u6d3b\u5316\u56e0\u5b50\u662f\u4e00\u7a2e\u6709\u6548\u7684\u4fc3\u708e\u6027\u78f7\u8102(pro-inflammatory phospholipid)\uff0c\u540c\u6642\u9084\u8ca0\u8cac\u6c34\u89e3\u6c27\u5316\u4fee\u98fe(hydrolyzing oxidatively modified)\u7684\u591a\u4e0d\u98fd\u548c\u8102\u80aa\u9178(polyunsaturated fatty acids)\u3002 Lp-PLA2 \u7684\u9176\u4fc3\u4f5c\u7528\u7522\u7269\u8207\u52d5\u8108\u7ca5\u6a23\u786c\u5316(atherosclerosis)\u7684\u767c\u5c55\u6709\u95dc\uff0c\u4e26\u8207\u51a0\u5fc3\u75c5(coronary heart disease)\u548c\u4e2d\u98a8(stroke)\u7684\u98a8\u96aa\u589e\u52a0\u5448\u6b63\u76f8\u95dc\u3002<\/p>\n

Muc2\u75c5\u7406\u5b78\u6297\u9ad4\uff1a<\/span>\u7c98\u86cb\u767d 2(Mucin 2)\uff0c\u4e5f\u7a31\u70ba MUC2\uff0c\u662f\u4e00\u7a2e\u7de8\u78bc\u7c98\u86cb\u767d\u5bb6\u65cf(mucin protein family)\u6210\u54e1\u7684\u4eba\u985e\u57fa\u56e0\u3002\u7531\u8a72\u57fa\u56e0\u7de8\u78bc\u7684\u86cb\u767d\u8cea\u5f62\u6210\u4fdd\u8b77\u8178\u8154(gut lumen)\u7684\u4e0d\u6eb6\u6027\u7c98\u6db2\u5c4f\u969c\u3002\u5728\u6b63\u5e38\u7d50\u8178(normal colon)\u3001\u4e73\u817a(breast)\u3001\u524d\u5217\u817a(prostate)\u548c\u553e\u6db2\u817a(salivary gland)\u7b49\u4eba\u9ad4\u7d44\u7e54\u4ee5\u53ca\u80c3\u8178\u9053(gastrointestinal)\u3001\u7d50\u8178(colonic)\u3001\u4e73\u817a(breast)\u548c\u524d\u5217\u817a\u816b\u7624(prostate neoplasia)\u4e2d\u6aa2\u6e2c\u5230 MUC2 \u8868\u9054\u3002<\/p>\n

\u7d30\u80de\u89d2\u86cb\u767d 18 (Cytokeratin 18) \u75c5\u7406\u5b78\u6297\u9ad4\uff1a<\/span>\u7d30\u80de\u89d2\u86cb\u767d 18 (Cytokeratin 18, CK 18) \u662f\u4e00\u7a2e 45kDa \u7684\u86cb\u767d\u8cea\uff0c\u5c6c\u65bc\u9178\u6027\u985e\u578b\u7684\u7d30\u80de\u89d2\u86cb\u767d(cytokeratins)\uff0c\u901a\u5e38\u5728\u7c21\u55ae\u7684\u975e\u5206\u5c64\u4e0a\u76ae\u7d30\u80de(non-stratified epithelia)\u4e2d\u8868\u9054\u3002\u7136\u800c\uff0cCK 18 \u4e5f\u5728\u79fb\u884c\u4e0a\u76ae(transitional epithelium)\u7684\u57fa\u5e95\u7d30\u80de\u548c\u8868\u5c64\u7d30\u80de\u4ee5\u53ca\u8907\u96dc\u4e0a\u76ae(complex epithelia)\u7684\u7ba1\u8154\/\u5206\u6ccc\u7d30\u80de(luminal\/secretory cells)\u4e2d\u8868\u9054\u3002 CK 18 \u6297\u9ad4\u5728\u8d77\u6e90\u65bc\u7c21\u55ae\u548c\u817a\u9ad4\u4e0a\u76ae(glandular epithelium)\u7684\u817a\u764c(Adenocarcinomas)\u4ee5\u53ca\u9c57\u72c0\u7d30\u80de\u764c(Squamous Carcinoma)\u7684\u4f4e\u5206\u5316\u816b\u7624\u7d30\u80de\u4e2d\u5448\u967d\u6027\u67d3\u8272\u3002<\/p>\n

MLH1\u75c5\u7406\u5b78\u6297\u9ad4\u00a0<\/span>\u662f\u4e00\u7a2e\u932f\u914d\u4fee\u5fa9\u86cb\u767d(mismatch repair protein)\uff0c\u8207 MSH2\u3001MSH6 \u548c PMS2 \u4e00\u8d77\u53c3\u8207\u7dad\u6301\u907a\u50b3\u4fe1\u606f\u7684\u5b8c\u6574\u6027\u3002\u9019\u7a2e\u86cb\u767d\u8cea\u901a\u5e38\u8207\u907a\u50b3\u6027(hereditary)\u975e\u606f\u8089\u75c5\u6027\u7d50\u76f4\u8178\u764c(non-polyposis colorectal cancer)\u6709\u95dc\uff0c\u56e0\u70ba MLH1 \u57fa\u56e0\u5728\u60a3\u6709\u9019\u7a2e\u764c\u75c7\u7684\u60a3\u8005\u4e2d\u7d93\u5e38\u767c\u751f\u7a81\u8b8a\u3002\u7814\u7a76\u8868\u660e\uff0cMLH1 \u5728\u5927\u90e8\u5206\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\u6027(microsatellite instability)\u4ee5\u53ca\u5b50\u5bae\u5167\u819c\u764c(endometrial)\u548c\u5375\u5de2\u764c(ovarian cancers)\u60a3\u8005\u4e2d\u5b58\u5728\u7f3a\u9677\u3002\u7576\u5728 IHC \u9762\u677f\u4e2d\u8207 MSH6\u3001MSH2 \u548c PMS2 \u914d\u5c0d\u6642\uff0c\u6297 MLH1 \u7684\u4f7f\u7528\u5f97\u5230\u512a\u5316\u3002<\/p>\n

HER2\u75c5\u7406\u5b78\u6297\u9ad4:<\/span><\/p>\n

HER2\u5728 10-20% \u7684\u4e73\u817a\u764c\u60a3\u8005(breast cancer patients)\u4e2d\u88ab\u8b58\u5225\u51fa\u4f86\u3002 Her2\/Neu (c-erbB-2) \u539f\u764c\u57fa\u56e0(proto-oncogene)\u662f\u4e00\u7a2e\u8de8\u819c\u53d7\u9ad4\u916a\u6c28\u9178\u6fc0\u9176(transmembrane receptor tyrosine kinase)\uff0c\u5728\u8a31\u591a\u764c\u75c7\u4e2d\u90fd\u6709\u81e8\u5e8a\u8868\u73fe\u3002 c-erbB-2 \u86cb\u767d\u7684\u904e\u5ea6\u8868\u9054(Overexpression)\u8207\u5c0e\u7ba1\u4e73\u817a\u764c(ductal breast cancer)\u4ee5\u53ca\u80ba\u817a\u764c(pulmonary)\u548c\u80c3\u817a\u764c(gastric adenocarcinomas)\u6709\u95dc\u3002Her2 \u548c p53 \u4e4b\u9593\u7684\u76f8\u95dc\u6027\u4e5f\u5df2\u88ab\u8b49\u660e\uff0c\u56e0\u70ba\u9019\u5169\u7a2e\u86cb\u767d\u7684\u904e\u5ea6\u8868\u9054\u8207\u8180\u80f1\u764c\u65e9\u671f\u4fb5\u8972(early invasion)\u548c\u8f49\u79fb(metastasis)\u6709\u95dc\u3002<\/p>\n

Ki-67\u00a0<\/span>\u662f\u4e00\u7a2e\u6838\u975e\u7d44\u86cb\u767d(nuclear non-histone protein)\uff0c\u5728\u975c\u6b62\u7d30\u80de(quiescent cells)\u4e2d\u4ee5\u4f4e\u6c34\u5e73\u5b58\u5728\uff0c\u4f46\u5728\u589e\u6b96\u7d30\u80de(proliferating cells)\u4e2d\u589e\u52a0\uff0c\u5c24\u5176\u662f\u5728 G2\u3001M \u548c S \u671f\u5f8c\u534a\u671f\u3002\u56e0\u6b64\uff0cKi-67 \u53cd\u61c9\u6027\uff08\u5b9a\u7fa9\u70ba\u901a\u904e IHC \u67d3\u8272\u6e2c\u91cf\u7684\u67d3\u8272\u967d\u6027\u7684\u816b\u7624\u7d30\u80de\u767e\u5206\u6bd4\uff09\u662f\u7d30\u80de\u589e\u6b96(cell proliferation)\u7684\u7279\u7570\u6027\u6838\u6a19\u8a18(nuclear marker )\u3002\u904e\u5ea6\u8868\u9054\u7d93\u5e38\u51fa\u73fe\u5728\u5404\u7a2e\u60e1\u6027\u7d44\u7e54(malignant tissues )\u4e2d\uff0c\u4e26\u4e14\u8207\u60a3\u6709\u795e\u7d93\u5167\u5206\u6ccc\u816b\u7624(neuroendocrine tumor)\u7684\u500b\u9ad4\u7684\u8f03\u5dee\u5b58\u6d3b\u7387\u76f8\u95dc\u3002>>IHC\u75c5\u7406\u5b78\u6297\u9ad4-Ki-67\u00a0\u6297\u9ad4<\/a>\u00a0<\/span><\/strong><\/span><\/p>\n

\"Better<\/p>\n

Exosome \u7814\u7a76\u5de5\u5177\/\u764c\u75c7\u76f8\u95dcExosomal Protein Marker<\/strong><\/span>–IReal Biotechnology<\/span><\/span><\/p>\n

IREAL\u63d0\u4f9b\u591a\u7a2e\u9ad8\u8cea\u91cf\u5916\u6ccc\u9ad4(exosomes)\u55ae\u591a\u682a\u6297\u9ad4 (IREAL Antibody)\uff0c\u5305\u62ecCD9(#IR300-981)<\/a><\/span>\u3001CD63(#IR301-983)<\/a><\/span>\u3001CD81(#IR302-986)<\/a><\/span>\u3001Flotillin-1(#IR304-990)<\/a>\u3001Alix(#IR303-988)<\/a><\/span>\u7b2c\u4e09\u65b9\u9a57\u8b49IHC\/IF\/WB\u6297\u9ad4\u3002\u5916\u6ccc\u9ad4(exosomes)\u53e6\u6709\u63d0\u4f9b\u5957\u7d44\u578b\u5f0f\u7684\u6297\u9ad4Panel\u5957\u7d44<\/a>\u3002<\/span><\/p>\n

\u8b58\u5225\u5916\u6ccc\u9ad4(exosomes)\u7684\u6700\u5e38\u898b\u8de8\u819c\u6a19\u8a18\u4f86\u81ea\u56db\u8de8\u819c\u86cb\u767d\u5bb6\u65cf\uff08CD63 \u3001CD81 \u548c CD9\uff09\u3002\u8a72\u5bb6\u65cf\u4e2d\u7684\u86cb\u767d\u8cea\u5177\u6709\u56db\u500b\u8de8\u819c\u5340\u57df\uff0c\u4e26\u4e14\u5b9a\u4f4d\u65bc\u8cea\u819c\u4e2d\u5bcc\u542b\u56db\u8de8\u819c\u86cb\u767d\u7684\u5fae\u57df (\u00a0tetraspanin enriched microdomains, TEM)\u3002\uff08CD63 \u3001CD81 \u3001 CD9\u53caCD82\uff09\u8207\u7c98\u9644\u5206\u5b50(\u00a0adhesion molecules)\u3001\u8de8\u819c\u53d7\u9ad4(\u00a0transmembrane receptors)\u548c\u7d30\u80de\u5167\u4fe1\u865f\u86cb\u767d(intracellular signaling proteins)\u76f8\u95dc\uff0c\u4ee5\u4fc3\u9032\u548c\u8abf\u7bc0\u4fe1\u865f(\u00a0signaling events)\u4e8b\u4ef6\u3002\u9ad8\u8cea\u91cf\u5916\u6ccc\u9ad4(exosomes)\u55ae\u591a\u682a\u6297\u9ad4 (IREAL Antibody)\uff0c\u63d0\u4f9b\u60a8\u66f4\u591aExosome \u7814\u7a76\u5de5\u5177\uff0c\u53ef\u61c9\u7528\u65bcIHC\/IF\/WB\u6297\u9ad4\u3002<\/p>\n

\"\u7db2\u7ad9\u898f\u683c\u5c0f\u5716<\/p>\n

BRAND\/AGENCY\/<\/strong>\u53f0\u7063\u4ee3\u7406\u5546<\/strong><\/span>\/<\/span>\u00a0<\/a><\/span><\/strong>IREAL<\/strong>\u827e\u92b3\u53f0\u7063\u4ee3\u7406\u5546<\/strong><\/a><\/span><\/span><\/p>\n

IREAL\u827e\u92ed\u5b98\u7db2\u00a0https:\/\/www.irealbio.com\/<\/a><\/span><\/p>\n

IREAL\u827e\u92ed\u751f\u7269\u79d1\u6280\u63d0\u4f9b\u6642\u4e0b\u71b1\u9580\u7814\u7a76\u9818\u57dfEMT marker\u3001Apoptosis\u3001ER stress\u3001Cell Cycle\u3001Autophagy\u53caNeuroscience\u7b49\u5e38\u7528\u6297\u9ad4\uff0c\u4e26\u63d0\u4f9b\u5ba2\u88fd\u5316\u6297\u9ad4\u670d\u52d9\u5e73\u53f0\u3002iReal\u00a0\u827e\u92ed\u751f\u7269\u79d1\u6280\u63d0\u4f9b\u6642\u4e0b\u71b1\u9580\u7814\u7a76\u9818\u57dfEMT marker\u3001Apoptosis\u3001ER stress\u3001Cell Cycle\u3001Autophagy\u53caNeuroscience\u7b49\u5e38\u7528\u6297\u9ad4\uff0c\u4e26\u63d0\u4f9b\u5ba2\u88fd\u5316\u6297\u9ad4\u670d\u52d9\u5e73\u53f0\u3002iReal \u827e\u92b3\u751f\u6280\u7368\u5bb6\u6253\u9020\u51faMonoclonal-like Polyclonal Antibody\uff0c\u514d\u75ab\u539f(Immunogen)\u70ba\u61c9\u7528\u77ed\u93c8\u80dc\u80bd(peptide)\u70ba\u6297\u539f\u8a2d\u8a08\u51fa\u767c\u9ede\uff0c\u6311\u9078\u5404\u86cb\u767d\u6700\u4f73\u7684\u4f4d\u9ede(epitope) \u8fa8\u8b58\u4f4d\u4f86\u8fa8\u8a8d\u76ee\u6a19\u86cb\u767d\uff0ciReal\u00a0\u514d\u75ab\u8840\u6e05\u7d93\u904e\u4e00\u9023\u591a\u6b65\u9a5f\u7684\u7d14\u5316\u904e\u7a0b(Affinity column purified )\uff0c\u53bb\u9664\u6389\u5404\u7a2e\u975e\u5c08\u4e00\u6027\u7684\u86cb\u767d\uff0c\u4ee5\u964d\u4f4e\u6297\u9ad4\u7684\u80cc\u666f\u503c\uff1b\u540c\u6642\u85c9\u7531\u5154\u5b50\u7368\u7279\u7684\u514d\u75ab\u7cfb\u7d71\u6240\u7522\u751f\u7684\u6297\u9ad4\uff0c\u80fd\u5920\u7522\u2f63\u8a31\u591a\u2f7c\u2fcf\u514d\u75ab\u7cfb\u7d71\u4e0d\u80fd\u8b58\u5225\u7684\u6297\u539f\u7684\u6297\u9ad4\u3002\u64c1\u6709\u5404\u5b78\u8853\u55ae\u4f4d\u771f\u5be6\u6578\u64da\u7684\u9a57\u8b49\uff0c\u4e26\u5177\u5099\u81e8\u5e8a\u9a57\u8b49\u898f\u683c\u7684\u6297\u9ad4\u54c1\u8cea\uff0c\u5927\u91cf\u4e14\u73fe\u8ca8\u4f9b\u61c9IHC\/IF\/WB\u6297\u9ad4\u3002<\/p>\n

\"IREAL\u827e\u92b3\u514d\u75ab\u67d3\u8272\u6297\u9ad4-\u592a\u9f0e\u751f\u6280_\u5de5\u4f5c\u5340\u57df<\/p>\n

\"\u578b\u9304\u4e0b\u8f09\"<\/p>\n

\"\"<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

IHC\/WB\/IF\/IP\u7814\u7a76\u5de5\u5177-Angiogenesis \/ Endothelial Antibodies& […]<\/p>\n","protected":false},"author":3,"featured_media":38534,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5264],"tags":[5445],"_links":{"self":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/40031"}],"collection":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40031"}],"version-history":[{"count":3,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/40031\/revisions"}],"predecessor-version":[{"id":40096,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/40031\/revisions\/40096"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/38534"}],"wp:attachment":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40031"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}